272TiP HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC)

Pascual, Tomás; D.G., Stover,; Thuerigen, A.; Perou, CM; Ciruelos, Eva; Tejerina, A. Casas Fernandez; Spears, P.; Roux, Estelle; Hu, Hao; Lu, Y-S; Tolaney, Sara M.; Partridge, Ann H.; Javierre, G. Villacampa; Cafiero, J.M. Ferrero; Carey, L.; Prat, Aleix

doi:10.1016/j.annonc.2022.07.1856

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…39 Perhaps, we will further elucidate this question with the Harmonia Trial, a prospective Phase III trial that endeavors to compare the progression-free survival of ribociclib and palbociclib with endocrine therapy in the treatment of HR +/HER2advanced breast cancer. 40 Ultimately, we may determine which of the three CDK4/6 inhibitors is the most efficacious and coincides with a more amenable tolerability profile; until then, perhaps ribociclib may be indicated for pre/perimenopausal patients (e.g. age < 40 years), as evidenced in the MONALEESA-7 study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer

Micha,

Rettenmaier,

Bohart

et al. 2024

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective Despite the relatively high cure rates in early-stage breast cancer, advanced and metastatic breast cancer cases are associated with more inauspicious patient outcomes. Fortunately, with the advent of cyclin-dependent kinase (CDK)4/6 inhibitors (e.g. palbociclib, ribociclib, and abemaciclib) with endocrine therapy, survival in advanced and metastatic breast cancer has appreciably improved. In the current review, we discuss these distinctions and the concomitant implications associated with the individual CDK4/6 inhibitors. Data sources We conducted an extensive PubMed search comprising several review articles on the topic of advanced or metastatic breast cancer treatment, with specific terms that included CDK4/6 inhibitors, treatment, and breast cancer. Data summary Palbociclib, ribociclib, and abemaciclib have exhibited superior progression-free survival differences compared to endocrine therapy alone. However, there are differences among the various CDK4/6 inhibitors with regard to overall survival, tolerability and quality of life. Conclusions Ribociclib may be indicated for pre/perimenopausal patients, whereas abemaciclib is potentially recommended to address endocrine-resistant or visceral disease. Alternatively, palbociclib is associated with lower discontinuation rates than abemaciclib and unlike ribociclib, QTc prolongation is not observed with palbociclib.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%